A Phase 2 interventional study of Placebo and TAK-079 in Primary Immune Thrombocytopenia, sponsored by Takeda. Completed at 55 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain — 14 open to participants now, 18 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Spain.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, this one is the 33rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2020, is one of 11 in phase 2, and was the 22nd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →14 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain are open now. Recruiting first, the newest first:
TargED Biopharmaceuticals B.V. · Sites in Spain
Ages 18+
CRISPR Therapeutics AG · Sites in Spain, United States, Germany
Ages 18+
Incyte Corporation · Sites in Spain, United States, Australia and 4 more countries
Ages 18+
Sanofi · Sites in Spain, United States, Austria and 7 more countries
Ages 18+
argenx · Sites in Spain, France, Germany and 7 more countries
Ages 12–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 23
First in 2006; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 69 across the 44 interventional studies, 131 across the 6 observational. Of the 31 that completed or were terminated, 21 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 50 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 6 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
5 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT07007962Phase 3SanofiStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | 2027-11-05 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT07043946Climb Bio, Inc.A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | 2027-08 |
| NCT07104565Incyte CorporationStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | 2027-09-23 |
Add all 5 to your calendar (.ics) → With an account.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot.
The main aim of the study is to check for side effects from taking TAK-079 at three different dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people with ITP.
In addition to receiving stable background therapy for ITP, participants will receive an injection of either TAK-079 or a placebo once a week for 2 months. A placebo looks like TAK-079 but will not have any medicine in it. After treatment, all participants will be followed-up for another 2 months.
Then, participants who received TAK-079 will continue to be followed-up for an extra 4 months. Participants who received the placebo and would like to receive TAK-079 may be able to do this in an extension period in the study.
The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have primary immune thrombocytopenia (ITP). This study will evaluate the safety and biologic activity of TAK-079 or matching placebo in combination with stable ITP background therapy.
The study will enroll approximately 36 to 54 participants. In Part A of the study, participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups. Those who received placebo in this period will have the choice to receive TAK-079 after a safety follow-up period and will be randomized to one of the two open-label TAK-079 treatment arms. An unblinded safety review will take place once a minimum of 24 evaluable participants are available for analysis in Part A to decide whether to open enrollment into Part B.
In Part B participants will be randomly assigned to one of two treatment groups. Those who received placebo in this period will have the choice to receive study drug after a safety follow-up period in a single open-label TAK-079 treatment arm.
This multi-center trial will be conducted worldwide. All participants will be followed for at least 8 weeks in a Safety Follow-up Period, and a 16-week Long-term Follow-up Period after the 8 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least 4 weeks before dosing.
Exclusion Criteria:
10 Has had an opportunistic infection ≤12 weeks before initial study dosing or is currently undergoing treatment for a chronic opportunistic infection, such as tuberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received TAK-079 placebo-matching injection subcutaneously (SC), once weekly (QW) for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded short follow-up period (SFP) up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in Open-label Extension (OLE) Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded long follow-up period (LFP) up to Week 32.
Drug: Placebo
Participants received TAK-079 100 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.
Drug: TAK-079
Participants received TAK-079 300 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.
Drug: TAK-079
Participants received TAK-079 600 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.
Drug: TAK-079
Participants who received placebo in double-blind Part A and opted to receive treatment with TAK-079 were randomized to receive TAK-079 100 mg, SC injection, QW for 8 weeks in OLE Period of Part A. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.
Drug: TAK-079
Participants who received placebo in double-blind Part A and opted to receive treatment with TAK-079 were randomized to receive TAK-079 300 mg, SC injection, QW for 8 weeks in OLE Period of Part A. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.
Drug: TAK-079
Participants who received placebo in double-blind Part B and opted to receive treatment with TAK-079 received TAK-079 600 mg, SC injection, QW for 8 weeks in OLE Period of Part B. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.
Drug: TAK-079
TAK-079 placebo-matching SC injection.
TAK-079 SC injection.
Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading to TAK-079 Discontinuation
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with the treatment. SAE means any untoward medical occurrence that at any dose: a) results in death; b) is life-threatening; c) requires inpatient hospitalization or prolongation of an existing hospitalization; d) results in persistent or significant disability or incapacity; e) is a congenital anomaly/birth defect; f) is a medically important event. TEAEs were defined as an AE having a start date and time equal to or later than the start date and time of the first dose of investigational medicinal product (IMP). Percentages were rounded off to the nearest single decimal place.
Time frame: Up to Week 32 in each Period of the study
Percentage of Participants With Platelet Response at Weeks 16 and 32
Platelet response is defined as a platelet count ≥50,000/microliter (μL) and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
Time frame: At Weeks 16 and 32
Percentage of Participants With Complete Platelet Response at Weeks 16 and 32
Complete platelet response is defined as a platelet count ≥100,000/μL on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
Time frame: At Weeks 16 and 32
Percentage of Participants With Clinically Meaningful Platelet Response at Weeks 16 and 32
A clinically meaningful platelet response is defined as a platelet count ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
Time frame: At Weeks 16 and 32
Percentage of Participants With Hemostatic Platelet Response at Weeks 16 and 32
A hemostatic platelet response is defined for participants with a baseline platelet count of \<15,000/μL who achieved a platelet count of ≥30,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
Time frame: At Weeks 16 and 32
Participants took part in the study at 24 investigative sites globally from 09 November 2020 to 29 April 2024.
| Milestone | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Started | 13 | 9 | 8 | 11 | 0 | 0 | 0 |
| Completed | 12 | 7 | 8 | 9 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with the treatment. SAE means any untoward medical occurrence that at any dose: a) results in death; b) is life-threatening; c) requires inpatient hospitalization or prolongation of an existing hospitalization; d) results in persistent or significant disability or incapacity; e) is a congenital anomaly/birth defect; f) is a medically important event. TEAEs were defined as an AE having a start date and time equal to or later than the start date and time of the first dose of investigational medicinal product (IMP). Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Grade 3 or Higher TEAE | 23.1 | 22.2 | 0 | 27.3 | 0 | 0 | 25.0 |
| Treatment Emergent SAE | 7.7 | 22.2 | 0 | 18.2 | 25.0 | 0 | 0 |
| TEAEs Leading to TAK-079 Discontinuation | 0 | 22.2 | 0 | 18.2 | 25.0 | 0 | 0 |
Platelet response is defined as a platelet count ≥50,000/microliter (μL) and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Week 16 | 23.08 (5.04 to 53.81) | 66.67 (29.93 to 92.51) | 62.50 (24.49 to 91.48) | 90.91 (58.72 to 99.77) | 50.00 (6.76 to 93.24) | 50.00 (6.76 to 93.24) | 25.00 (0.63 to 80.59) |
| Week 32 | — | 66.67 (29.93 to 92.51) | 62.50 (24.49 to 91.48) | 90.91 (58.72 to 99.77) | 50.00 (6.76 to 93.24) | 50.00 (6.76 to 93.24) | 25.00 (0.63 to 80.59) |
Complete platelet response is defined as a platelet count ≥100,000/μL on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Week 16 | 0 (0.00 to 24.71) | 55.56 (21.20 to 86.30) | 50.00 (15.70 to 84.30) | 81.82 (48.22 to 97.72) | 0 (0.00 to 60.24) | 25.00 (0.63 to 80.59) | 25.00 (0.63 to 80.59) |
| Week 32 | — | 55.56 (21.20 to 86.30) | 50.00 (15.70 to 84.30) | 81.82 (48.22 to 97.72) | 25.00 (0.63 to 80.59) | 25.00 (0.63 to 80.59) | 25.00 (0.63 to 80.59) |
A clinically meaningful platelet response is defined as a platelet count ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Week 16 | 30.77 (9.09 to 61.43) | 66.67 (29.93 to 92.51) | 75.00 (34.91 to 96.81) | 90.91 (58.72 to 99.77) | 75.00 (19.41 to 99.37) | 50.00 (6.76 to 93.24) | 25.00 (0.63 to 80.59) |
| Week 32 | — | 66.67 (29.93 to 92.51) | 75.00 (34.91 to 96.81) | 90.91 (58.72 to 99.77) | 75.00 (19.41 to 99.37) | 50.00 (6.76 to 93.24) | 25.00 (0.63 to 80.59) |
A hemostatic platelet response is defined for participants with a baseline platelet count of \<15,000/μL who achieved a platelet count of ≥30,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Week 16 | 0 (0.00 to 52.18) | 40.00 (5.27 to 85.34) | 25.00 (0.63 to 80.59) | 100.00 (39.76 to 100.00) | 100.00 (15.81 to 100.00) | 100.00 (2.50 to 100.00) | 0 (0.00 to 70.76) |
| Week 32 | — | 40.00 (5.27 to 85.34) | 25.00 (0.63 to 80.59) | 100.00 (39.76 to 100.00) | 100.00 (15.81 to 100.00) | 100.00 (2.50 to 100.00) | 0 (0.00 to 70.76) |
Collected over Up to Week 32 in each Period of the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A & B: Double Blind Period: Placebo | 0/13 (0%) | 1/13 (7.7%) | 9/13 (69.2%) |
| Part A: Double Blind Period: TAK-079 100 mg | 0/9 (0%) | 2/9 (22.2%) | 7/9 (77.8%) |
| Part A: Double Blind Period: TAK-079 300 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part B: Double Blind Period: TAK-079 600 mg | 0/11 (0%) | 2/11 (18.2%) | 6/11 (54.5%) |
| Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | 0/4 (0%) | 1/4 (25%) | 2/4 (50%) |
| Part A: OLE Period: TAK-079 300 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part B: OLE Period: TAK-079 600 mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/13 | 0/9 | 0/8 | 0/11 | 1/4 | 0/4 | 0/4 |
| Conjunctivitis allergicEye disorders | 0/13 | 1/9 | 0/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| Immune thrombocytopeniaBlood and lymphatic system disorders | 0/13 | 1/9 | 0/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| Staphylococcal bacteraemiaInfections and infestations | 0/13 | 1/9 | 0/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| Acute kidney injuryRenal and urinary disorders | 0/13 | 0/9 | 0/8 | 1/11 | 0/4 | 0/4 | 0/4 |
| Pyelonephritis chronicInfections and infestations | 0/13 | 0/9 | 0/8 | 1/11 | 0/4 | 0/4 | 0/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/13 | 0/9 | 0/8 | 1/11 | 0/4 | 0/4 | 0/4 |
| Haemorrhagic ovarian cystReproductive system and breast disorders | 1/13 | 0/9 | 0/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| Event | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Part A: Open-label Extension (OLE) Period: TAK-079 100 mg | Part A: OLE Period: TAK-079 300 mg | Part B: OLE Period: TAK-079 600 mg |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/13 | 0/9 | 2/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 0/13 | 0/9 | 2/8 | 0/11 | 0/4 | 0/4 | 0/4 |
| Anal fissureGastrointestinal disorders | 0/13 | 0/9 | 0/8 | 0/11 | 0/4 | 1/4 | 0/4 |
| AstheniaGeneral disorders | 2/13 | 0/9 | 0/8 | 0/11 | 0/4 | 0/4 | 1/4 |
| COVID-19Infections and infestations | 1/13 | 2/9 | 0/8 | 1/11 | 1/4 | 0/4 | 0/4 |
| ChillsGeneral disorders | 0/13 | 0/9 | 0/8 | 0/11 | 0/4 | 1/4 | 0/4 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/13 | 0/9 | 0/8 | 0/11 | 0/4 | 0/4 | 1/4 |
| Conjunctival haemorrhageEye disorders | 2/13 | 1/9 | 0/8 | 0/11 | 1/4 | 0/4 | 0/4 |
| ContusionInjury, poisoning and procedural complications | 2/13 | 0/9 | 0/8 | 0/11 | 0/4 | 0/4 | 1/4 |
| DizzinessNervous system disorders | 0/13 | 0/9 | 0/8 | 0/11 | 0/4 | 1/4 | 0/4 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.8 ± 15.86 | 49.0 ± 14.45 | 52.3 ± 16.59 | 48.4 ± 19.68 | 46.2 ± 17.03 |
| Sex: Female, Male(Participants) | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Total |
|---|---|---|---|---|---|
| Female | 9 | 5 | 5 | 9 | 28 |
| Male | 4 | 4 | 3 | 2 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 12 | 9 | 8 | 9 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Part A & B: Double Blind Period: Placebo | Part A: Double Blind Period: TAK-079 100 mg | Part A: Double Blind Period: TAK-079 300 mg | Part B: Double Blind Period: TAK-079 600 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 11 | 9 | 8 | 9 | 37 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2020 to primary completion in Apr 2024, 41 months.
Results were first posted in Jun 2025, 1 year 1 month after primary completion.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mezagitamab
Purpura, Thrombocytopenic, Idiopathic →